Selective HDAC class IIa inhibitors as potential therapeutics for Huntington\'s disease

被引：0
|
作者：
Burli, Roland [1 ]
Dominguez, Celia [2 ]
机构：
[1] BioFocus, Dept Med Chem, Saffron Walden CB10 1XL, Essex, England
[2] CHDI Fdn, Dept Med Chem, Los Angeles, CA 90045 USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2011年 / 242卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
240-MEDI
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Design, Synthesis, and Biological Evaluation of Potent and Selective Class IIa Histone Deacetylase (HDAC) Inhibitors as a Potential Therapy for Huntington's Disease
    Buerli, Roland W.
    Luckhurst, Christopher A.
    Aziz, Omar
    Matthews, Kim L.
    Yates, Dawn
    Lyons, Kathy. A.
    Beconi, Maria
    McAllister, George
    Breccia, Perla
    Stott, Andrew J.
    Penrose, Stephen D.
    Wall, Michael
    Lamers, Marieke
    Leonard, Philip
    Mueller, Ilka
    Richardson, Christine M.
    Jarvis, Rebecca
    Stones, Liz
    Hughes, Samantha
    Wishart, Grant
    Haughan, Alan F.
    O'Connell, Catherine
    Mead, Tania
    McNeil, Hannah
    Vann, Julie
    Mangette, John
    Maillard, Michel
    Beaumont, Vahri
    Munoz-Sanjuan, Ignacio
    Dominguez, Celia
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (24) : 9934 - 9954
  • [2] Selective class IIa HDAC inhibitors: myth or reality
    Di Giorgio, Eros
    Gagliostro, Enrico
    Brancolini, Claudio
    [J]. CELLULAR AND MOLECULAR LIFE SCIENCES, 2015, 72 (01) : 73 - 86
  • [3] Selective class IIa HDAC inhibitors: myth or reality
    Eros Di Giorgio
    Enrico Gagliostro
    Claudio Brancolini
    [J]. Cellular and Molecular Life Sciences, 2015, 72 : 73 - 86
  • [4] Design of selective phosphodiesterase inhibitors and their potential utility for the treatment of Huntington\'s disease
    Verhoest, Patrick R.
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 242
  • [5] Epigenetics in osteoarthritis: Potential of HDAC inhibitors as therapeutics
    Khan, Nazir M.
    Haqqi, Tariq M.
    [J]. PHARMACOLOGICAL RESEARCH, 2018, 128 : 73 - 79
  • [6] Design of class selective HDAC inhibitors
    Estiu, Guillermina
    Harrison, Chris
    Wiest, Olaf
    Mazitschek, Ralph
    Bradner, James
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 233 : 615 - 615
  • [7] Novel Selective Calpain 1 Inhibitors as Potential Therapeutics in Alzheimer's Disease
    Fa, Mauro
    Zhang, Hong
    Staniszewski, Agnieszka
    Saeed, Faisal
    Shen, Li W.
    Schiefer, Isaac T.
    Siklos, Marton I.
    Tapadar, Subhasish
    Litosh, Vladislav A.
    Libien, Jenny
    Petukhov, Pavel A.
    Teich, Andrew F.
    Thatcher, Gregory R. J.
    Arancio, Ottavio
    [J]. JOURNAL OF ALZHEIMERS DISEASE, 2016, 49 (03) : 707 - 721
  • [8] Therapeutics in Huntington's Disease
    Killoran, Annie
    Biglan, Kevin M.
    [J]. CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2012, 14 (02) : 137 - 149
  • [9] Therapeutics in Huntington’s Disease
    Annie Killoran
    Kevin M. Biglan
    [J]. Current Treatment Options in Neurology, 2012, 14 : 137 - 149
  • [10] Discovery of brain penetrant JNK3 inhibitors as potential therapeutics for the treatment of Huntington\'s disease
    McGee, Kevin F.
    Duffy, Bryan C.
    Song, Ren Hua
    Conlon, Michael P.
    Kitchen, Douglas
    Lamers, Marieke
    Leonard, Philip
    Irigoyen, Macarena
    Luche, Michele
    Adolphson, Janet
    Bai, Mei
    Newell, Ryan
    Pastor, Eric
    Khademi, Shawn
    Hultman, Monica
    Ghandour, Haifa
    Michels, Peter
    Toledo-Sherman, Leticia
    Kiselyov, Alexander S.
    Beconi, Maria
    Munoz-Sanjuan, Ignacio
    Bard, Jonathan
    Dominguez, Celia
    Wityak, John
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 242
12345